Petros Pharmaceuticals, Inc.(NASDAQ : PTPI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||1.91%||78.62||0.7%||$1561.37m|
|JNJ||Johnson & Johnson||2.44%||164.02||0.7%||$1001.62m|
|BMY||Bristol-Myers Squibb Co.||0.83%||57.41||1.0%||$656.74m|
|LLY||Eli Lilly & Co.||0.69%||240.63||1.1%||$613.56m|
|NVO||Novo Nordisk A/S||1.09%||104.56||0.1%||$91.62m|
|EDSA||Edesa Biotech, Inc.||6.72%||8.26||0.0%||$75.63m|
|CRVS||Corvus Pharmaceuticals, Inc.||0.87%||4.66||0.7%||$56.99m|
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.